Granted Patent
B2
US 7,488,804 · App. 11/050,113 · Granted Feb 10, 2009
Modified fusion molecules for treatment of allergic disease
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention comprises a fusion molecule comprising a Fcε fragment sequence including functionally active CH2, CH3 and CH4 domains of the constant region of an IgE heavy chain (CHε2-CHε3-CHε4 sequence) linked at its C-terminus to the N-terminus of a second polypeptide including functionally active hinge, CH2 and CH3 domains of the constant region of an IgG 1 heavy chain (γhinge-CHγ2-CHγ3 sequence), pharmaceutical compositions comprising the fusion molecule and methods of treatment using the fusion molecule.
Claims (1)
1. A fusion molecule comprising the polypeptide sequence CHε2-CHε3-CHε4-γhinge-CHγ2-CHγ3, wherein the sequence comprises the sequence of SEQ ID NO: 19.
Assignments (2)
CONFIRMATORY LICENSE
Recorded Mar 27, 2009
From: UNIVERSITY OF CALIFORNIA LOS ANGELES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 022459/0531 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 25, 2005
From: SAXON, ANDREW; ZHANG, KE; ZHU, DAOCHENG
To: REGENTS OF THE UNIVERISITY OF CALIFORNIA, THE
Reel/Frame 016810/0783 →
Continuity (1)